Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
Memorial Sloan-Kettering Cancer Center, New York, NY motzerr@mskcc.org.
Robert J
RJ
Motzer
Thomas E
TE
Hutson
Lauren
L
McCann
Keith
K
Deen
Toni K
TK
Choueiri
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D007191:Indazoles; D007211:Indoles / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011743:Pyrimidines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D000077210:Sunitinib
D020533:Angiogenesis Inhibitors; D007191:Indazoles; D007211:Indoles; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; C516667:pazopanib; D000077210:Sunitinib